XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to assess the efficacy of XP13512 taken once daily
compared to placebo for the treatment of patients suffering from Restless Legs Syndrome
(RLS).